# PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

> **NCT00867815** · PHASE4 · TERMINATED · sponsor: **Bayer** · enrollment: 10 (actual)

## Conditions studied

- Anterior Ischemic Optic Neuropathy

## Interventions

- **DRUG:** Diagnostic procedures

## Key facts

- **NCT ID:** NCT00867815
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-07-13
- **Primary completion:** 2017-12-29
- **Final completion:** 2018-03-28
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2019-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00867815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00867815, "PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00867815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*